JP Morgan Private Wealth Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

JP Morgan Private Wealth Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$263K	Buy	2,277 +92	+4%	+$9.88K	﹤0.01%	1533
2023 Q2	$225K	Sell	2,185 -204	-9%	-$21.5K	﹤0.01%	1349
2023 Q1	$261K	Sell	2,389 -9,695	-80%	-$1.07M	﹤0.01%	1733
2022 Q4	$1.38M	Buy	12,084 +1,110	+10%	+$92.2K	﹤0.01%	993
2022 Q3	$679K	Buy	10,974 +832	+8%	+$58.1K	﹤0.01%	1330
2022 Q2	$809K	Buy	10,142 +175	+2%	+$16.6K	﹤0.01%	1241
2022 Q1	$1.05M	Sell	9,967 -9,002	-47%	-$877K	﹤0.01%	1204
2021 Q4	$2.04M	Buy	18,969 +882	+5%	+$96.2K	﹤0.01%	908
2021 Q3	$1.98M	Buy	18,087 +8,496	+89%	+$882K	﹤0.01%	905
2021 Q2	$898K	Buy	9,591 +4,237	+79%	+$390K	﹤0.01%	1248
2021 Q1	$493K	Sell	5,354 -493	-8%	-$41.6K	﹤0.01%	1319
2020 Q4	$428K	Buy	+5,847	New	+$435K	﹤0.01%	1347

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

JP Morgan Private Wealth Advisors's HZNP Position: Q3 2023 in Review

JP Morgan Private Wealth Advisors increased its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 4.2% in Q3 2023, buying an estimated $9.88K and bringing the position to 2,277 shares worth $263K. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

JP Morgan Private Wealth Advisors first reported a position in HZNP in Q4 2020 and has held it in 12 quarters since. The position peaked at $2.04M in Q4 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

JP Morgan Private Wealth Advisors held 2,277 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $263K as of Q3 2023.
JP Morgan Private Wealth Advisors bought 92 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $9.88K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up ﹤0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #1533 holding.
JP Morgan Private Wealth Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2020 and has held it in 12 quarters since.
JP Morgan Private Wealth Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $2.04M in Q4 2021.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.